Innovative Vision Products, Inc., County of New Castle, Delaware, USA.
Cell Biochem Funct. 2011 Apr;29(3):183-206. doi: 10.1002/cbf.1737. Epub 2011 Mar 7.
The aging eye appears to be at considerable risk from oxidative stress. Lipid peroxidation (LPO) is one of the mechanisms of cataractogenesis, initiated by enhanced promotion of oxygen free radicals in the eye fluids and tissues and impaired enzymatic and non-enzymatic antioxidant defenses of the crystalline lens. The present study proposes that mitochondria are one of the major sources of reactive oxygen species (ROS) in mammalian and human lens epithelial cells and that therapies that protect mitochondria in lens epithelial cells from damage and reduce damaging ROS generation may potentially ameliorate the effects of free radical-induced oxidation that occur in aging ocular tissues and in human cataract diseases. It has been found that rather than complete removal of oxidants by the high levels of protective enzyme activities such as superoxide dismutase (SOD), catalase, lipid peroxidases in transparent lenses, the lens conversely, possess a balance between peroxidants and antioxidants in a way that normal lens tends to generate oxidants diffusing from lenticular tissues, shifting the redox status of the lens to become more oxidizing during both morphogenesis and aging. Release of the oxidants (O(2)(-)·, H(2)O(2) , OH·, and lipid hydroperoxides) by the intact lenses in the absence of respiratory inhibitors indicates that these metabolites are normal physiological products inversely related to the lens life-span potential (maturity of cataract) generated through the metal-ion catalyzed redox-coupled pro-oxidant activation of the lens reductants (ascorbic acid, glutathione). The membrane-bound phospholipid (PL) hydroperoxides escape detoxification by the lens enzymatic reduction. The lens cells containing these species would be vulnerable to peroxidative attack which trigger the PL hydroperoxide-dependent chain propagation of LPO and other damages in membrane (lipid and protein alterations). The increased concentrations of primary LPO products (diene conjugates, lipid hydroperoxides) and end fluorescent LPO products were detected in the lipid moiety of the aqueous humor samples obtained from patients with cataract as compared to normal donors. Since LPO is clinically important in many of the pathological effects and aging, new therapeutic modalities, such as patented N-acetylcarnosine prodrug lubricant eye drops, should treat the incessant infliction of damage to the lens cells and biomolecules by reactive lipid peroxides and oxygen species and "refashion" the affected lens membranes in the lack of important metabolic detoxification of PL peroxides. Combined in ophthalmic formulations with N-acetylcarnosine, mitochondria-targeted antioxidants are promising to become investigated as a potential tool for treating a number of ROS-related ocular diseases, including human cataracts.
衰老的眼睛似乎面临着很大的氧化应激风险。脂质过氧化(LPO)是白内障形成的机制之一,它是由眼液和组织中氧自由基的增强促进以及晶状体中酶和非酶抗氧化防御的受损引发的。本研究提出,线粒体是哺乳动物和人晶状体上皮细胞中活性氧(ROS)的主要来源之一,保护晶状体上皮细胞中的线粒体免受损伤并减少破坏性 ROS 生成的疗法可能潜在地改善自由基诱导的氧化对衰老眼组织和人白内障疾病的影响。已经发现,透明晶状体中高水平的保护酶活性(如超氧化物歧化酶[SOD]、过氧化氢酶、脂质过氧化物)并不能完全清除氧化剂,相反,晶状体在氧化剂和抗氧化剂之间保持平衡,正常晶状体倾向于从晶状体组织中扩散产生氧化剂,从而使晶状体的氧化还原状态在形态发生和衰老过程中变得更加氧化。在没有呼吸抑制剂的情况下,完整晶状体释放的氧化剂(O(2)(-)·、H(2)O(2)、OH·和脂质氢过氧化物)表明这些代谢物是正常的生理产物,与晶状体寿命潜力(白内障成熟度)成反比,这是通过金属离子催化的氧化还原偶联将晶状体还原剂(抗坏血酸、谷胱甘肽)激活生成的。膜结合的磷脂(PL)氢过氧化物逃避晶状体酶促还原的解毒。含有这些物质的晶状体细胞容易受到过氧化攻击的影响,从而引发 PL 氢过氧化物依赖性 LPO 链传播和膜(脂质和蛋白质改变)的其他损伤。与正常供体相比,从白内障患者的房水中获得的脂质部分检测到初级 LPO 产物(二烯轭合物、脂质氢过氧化物)和末端荧光 LPO 产物的浓度增加。由于 LPO 在许多病理效应和衰老中具有临床重要性,因此新的治疗方法,如专利的 N-乙酰基肉碱前药润眼液,应该治疗活性脂质过氧化物和氧物种对晶状体细胞和生物分子的持续损伤,并在缺乏 PL 过氧化物重要代谢解毒的情况下“重塑”受影响的晶状体膜。与 N-乙酰基肉碱联合使用时,靶向线粒体的抗氧化剂有望成为治疗多种与 ROS 相关的眼部疾病(包括人白内障)的潜在工具。